FDA taps early pharma participants for PreCheck pilot aimed at strengthening US drug supply chain

The US Food and Drug Administration has selected seven pharmaceutical companies as early participants in a new pilot effort meant to improve oversight and resilience across the country’s drug supply chain. According to an industry report, Eli Lilly and Regeneron are among the first incumbents to be included in the agency’s “PreCheck” facility scheme.

FDA’s PreCheck pilot is being positioned as a framework to strengthen how drugs move through the supply chain, with an emphasis on reducing bottlenecks and improving confidence that facilities are operating under appropriate controls. The program centers on the role of drug manufacturing and related facilities, rather than the end product alone, and aims to streamline risk-based screening earlier in the process.

For Eli Lilly, inclusion in the initial cohort indicates that the company is participating in an FDA-led approach to modernize oversight of manufacturing inputs and production pathways. For Regeneron, the selection similarly places the company in the early group working through FDA’s plan to test whether pre-qualification or pre-screening mechanisms can make inspections and oversight more efficient.

The report describes the initiative as a “fast-track facility scheme,” language that underscores an expected benefit for both regulators and industry: faster movement of products through regulatory touchpoints, where appropriate, while still maintaining controls. The agency’s goal, as characterized in the report, is to bolster the US drug supply chain, a priority that has become more prominent amid recurring supply disruptions and heightened scrutiny of manufacturing capacity and compliance.

Drug supply chain risk management has increasingly shifted toward earlier intervention. Instead of waiting until products are already in distribution to detect problems, regulators have been looking for ways to evaluate facilities and processes before disruptions occur. In this context, FDA’s PreCheck pilot reflects a broader trend toward risk-based, data-driven oversight, where the timing of screening can matter as much as the screening itself.

Still, the disclosed details remain limited. The industry report identifies the initiative, describes it as a pilot, and names Lilly and Regeneron among the first wave of seven companies, but it does not provide specific operational parameters, eligibility criteria, or timelines for when products tied to participating facilities would receive any benefits. It also does not outline what additional standards or documentation the companies will need to provide beyond normal regulatory expectations.

Companies participating in the early phase may also be required to report on how the pilot affects inspection planning or shipment timelines, but the cited report does not say what metrics will be used to judge success. As a result, the degree to which PreCheck ultimately reduces delays, improves assurance, or changes regulatory workflows will likely depend on how the pilot is implemented and evaluated.